Target family: P2X receptors (type: lgic)
Target: P2X1

Ligand: αβ-meATP (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: ATP (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.25 pEC50
Reference (Journal): Purine and pyrimidine (P2) receptors as drug targets.
Published in: J Med Chem

Ligand: BzATP (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: Ip5I (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.5 pIC50
Reference (Journal): Diinosine pentaphosphate (IP5I) is a potent antagonist at recombinant rat P2X1 receptors.
Published in: Br J Pharmacol

Ligand: L-βγ-meATP (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: MRS2159 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
Published in: J Med Chem

Ligand: MRS 2219 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors.
Published in: J Med Chem

Ligand: NF023 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pIC50
Reference (Journal): Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors.
Published in: Neuropharmacology

Ligand: NF279 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pIC50
Reference (Journal): Antagonism by the suramin analogue NF279 on human P2X(1) and P2X(7) receptors.
Published in: Eur J Pharmacol

Ligand: NF279 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Journal): The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor.
Published in: Neuropharmacology

Ligand: NF449 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.300000190734863 pIC50
Reference (Journal): Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist.
Published in: Eur J Med Chem

Ligand: suramin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity: 6 pIC50
Reference (Journal): Purine and pyrimidine (P2) receptors as drug targets.
Published in: J Med Chem

Ligand: TNP-ATP (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Primary target: no
Median affinity: 8.899999618530273 pIC50
Reference (Journal): Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors.
Published in: Mol Pharmacol